These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39091145)

  • 1. Commentary on 'Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)'.
    Sah S; Verma A; Zahiruddin QS; Rustagi S
    HIV Med; 2024 Oct; 25(10):1177-1178. PubMed ID: 39091145
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
    Ring K; Smuk M; Shongwe M; Okonta L; Mackie NE; Ayres S; Barber TJ; Akodu J; Ferro F; Chilton D; Hurn E; Halai B; Barchi W; Ali A; Darko S; White G; Clarke E; Clark F; Ali B; Arumainayagam J; Quinn G; Boffito M; Byrne R; Naous N; Leung S; Umaipalan A; Thornton B; Bayliss D; McLoughlin C; Foster J; Waters L; Orkin C
    HIV Med; 2024 Oct; 25(10):1125-1134. PubMed ID: 38858222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing long-acting injectable cabotegravir and rilpivirine in Africa.
    Orkin C; Ring K
    Lancet Infect Dis; 2024 Oct; 24(10):1060-1061. PubMed ID: 38821072
    [No Abstract]   [Full Text] [Related]  

  • 4. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Cossu MV; D'Avolio A; Gervasoni C; Giacomelli A; Cattaneo D; Moschese D
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017524. PubMed ID: 38534104
    [No Abstract]   [Full Text] [Related]  

  • 6. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine.
    Ripamonti D; Borghetti A; Zazzi M
    J Antimicrob Chemother; 2024 Oct; 79(10):2720-2724. PubMed ID: 39066658
    [No Abstract]   [Full Text] [Related]  

  • 7. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda.
    Zakumumpa H; Alinaitwe A; Kyomuhendo M; Nakazibwe B
    BMC Infect Dis; 2024 Aug; 24(1):876. PubMed ID: 39198739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.
    Mazzitelli M; Avolio A; Carandina R; Parisi S; Wensing A; Cattelan A
    J Antimicrob Chemother; 2024 Aug; 79(8):2074-2076. PubMed ID: 38905150
    [No Abstract]   [Full Text] [Related]  

  • 16. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa.
    Steulet A; Obura B; Waitt C; Laker E; Nicol MR; Cresswell FV
    Br J Clin Pharmacol; 2024 Sep; 90(9):2079-2091. PubMed ID: 38923554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS).
    John M; Williams L; Nolan G; Bonnett M; Castley A; Nolan D
    HIV Med; 2024 Aug; 25(8):935-945. PubMed ID: 38644518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.